{"id":525466,"date":"2021-08-09T11:17:32","date_gmt":"2021-08-09T15:17:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/"},"modified":"2021-08-09T11:17:32","modified_gmt":"2021-08-09T15:17:32","slug":"fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/","title":{"rendered":"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Aug.  09, 2021  (GLOBE NEWSWIRE) &#8212; Fluidigm Corporation\u00a0(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event:<\/p>\n<p align=\"center\">UBS Genomics 2.0 and MedTech Innovations Summit<br \/>Wednesday, August 11, 2021<br \/>Laguna Beach, California<br \/>Panel presentation at 8:00 p.m. ET, 5:00 p.m. PT<\/p>\n<p>The panel presentation includes a Fluidigm Imaging Mass Cytometry\u2122 customer discussing spatial imaging. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will also participate in investor meetings.<\/p>\n<p>\n        <strong>About Fluidigm <\/strong><br \/>\n        <br \/>Fluidigm\u00a0(Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF<sup>\u00ae<\/sup>\u00a0and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B0PSXwfwiXqZdkO5mdZeWoSp7ApxdfEoBnWzujtI_2tp_tvveevt_tyYZGBIAdX2nbN0r32uIqOT0UNjyq8jMA==\" rel=\"nofollow noopener\" target=\"_blank\">fluidigm.com<\/a>.<\/p>\n<p>Fluidigm, the\u00a0Fluidigm\u00a0logo, Advanta, and CyTOF are trademarks and\/or registered trademarks of\u00a0Fluidigm Corporation\u00a0in\u00a0the United States\u00a0and\/or other countries.\u00a0All other trademarks are the sole property of their respective owners. The Advanta\u2122 Dx SARS-CoV-2 RT-PCR Assay is for <em>In Vitro<\/em> Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm\u00a0products are provided for Research Use Only. Not for use in diagnostic procedures.<\/p>\n<p>\n        <strong>Available Information<\/strong><br \/>\n        <br \/> We use our website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B0PSXwfwiXqZdkO5mdZeWiTzGp-Ub1pB9zSo65LeRbixvtcnpNyzAG9iEl3tDQokGniIpzJm_gGiMhIQGv0gCw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>fluidigm.com<\/u><\/a>), investor site (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Z9qD4PEp6-OxFchLaTgCYJY-AyhPqWTFL9FXoZg84J_aaHEA7HRNN-v2A4kwzS3maYR5caNChW7iIC0MczVQwlpmpdyq2ZHGxt4srOD3EE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>investors.fluidigm.com<\/u><\/a>), corporate Twitter account (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7D-rWWF-GOBkL2vfMtx7KuzOl0N8koyWvDaEe_qbWA6msUiIm1MKxbDXS4-zf-Hx37J-InNtWweIvH0jW_dTdg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>@fluidigm<\/u><\/a>), Facebook page (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qHHWv7lLbBkdsTJMo0URqgljN1COd4ybcBWcnWQ5UZ5NHnydkCC3LvwcYNB8v56OGmYeksxhTKfDnBWQ4yN6nZCjoDklInTcWWZTg_2K-SE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>facebook.com\/Fluidigm<\/u><\/a>), and LinkedIn page (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lt_Avxy2Vgy86a9XstiXfGXJtusSzrgq28G1yq9wLgmlpA58ucdjm4erHPa_0RWdFkrJjEEDuQuuf9EH-mUs_9IhNXMH473vj1vPAOA-jQVOV7LH-bkL78cL8IhrHqMcfLzzeSQUNZBTsTEhtt1gmTSLV8eWq5gOPB_KYdjSLeM=\" rel=\"nofollow noopener\" target=\"_blank\"><u>linkedin.com\/company\/fluidigm-corporation<\/u><\/a>) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases,\u00a0SEC\u00a0filings, public conference calls, and webcasts.<\/p>\n<p>Contacts:<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Peter DeNardo<br \/>415 389 6400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IdQrsceCv2Ixbbf6NMOa0xgk5YRNkYkPVpxuN5Ni2FXZwxB0SDCsfI-zp7sO_-pOyiFmNZqjzqGhpvOQ0RUcOw==\" rel=\"nofollow noopener\" target=\"_blank\">IR@fluidigm.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Mark Spearman<br \/>Senior Director, Corporate Communications<br \/>650 243 6621<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OleUiZkhr2S2m2W8meYgva350NpZhJw64wQVR9SqpfGXIBZAMWZvr8-JI-vAXVnd5QEOJpnYmZ8Xd7TY11lag_KP1AuOiTzpzOKXITW9tgy2XGzv-LbSZ8uUHfZXZHi6\" rel=\"nofollow noopener\" target=\"_blank\">mark.spearman@fluidigm.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzliODA5ZTAtNGQxYi00YmRhLWE3MzAtMzAyYTM0YWQ1NDYxLTEwMTUzOTE=\/tiny\/Fluidigm-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) &#8212; Fluidigm Corporation\u00a0(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations SummitWednesday, August 11, 2021Laguna Beach, CaliforniaPanel presentation at 8:00 p.m. ET, 5:00 p.m. PT The panel presentation includes a Fluidigm Imaging Mass Cytometry\u2122 customer discussing spatial imaging. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will also participate in investor meetings. About Fluidigm Fluidigm\u00a0(Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF\u00ae\u00a0and microfluidics technologies, we develop, manufacture, and market multi-omic solutions &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525466","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) &#8212; Fluidigm Corporation\u00a0(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations SummitWednesday, August 11, 2021Laguna Beach, CaliforniaPanel presentation at 8:00 p.m. ET, 5:00 p.m. PT The panel presentation includes a Fluidigm Imaging Mass Cytometry\u2122 customer discussing spatial imaging. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will also participate in investor meetings. About Fluidigm Fluidigm\u00a0(Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF\u00ae\u00a0and microfluidics technologies, we develop, manufacture, and market multi-omic solutions &hellip; Continue reading &quot;Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-09T15:17:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit\",\"datePublished\":\"2021-08-09T15:17:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/\"},\"wordCount\":379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/\",\"name\":\"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=\",\"datePublished\":\"2021-08-09T15:17:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/","og_locale":"en_US","og_type":"article","og_title":"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) &#8212; Fluidigm Corporation\u00a0(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations SummitWednesday, August 11, 2021Laguna Beach, CaliforniaPanel presentation at 8:00 p.m. ET, 5:00 p.m. PT The panel presentation includes a Fluidigm Imaging Mass Cytometry\u2122 customer discussing spatial imaging. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will also participate in investor meetings. About Fluidigm Fluidigm\u00a0(Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF\u00ae\u00a0and microfluidics technologies, we develop, manufacture, and market multi-omic solutions &hellip; Continue reading \"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-09T15:17:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit","datePublished":"2021-08-09T15:17:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/"},"wordCount":379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/","name":"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=","datePublished":"2021-08-09T15:17:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTUyNCM0MzQ4NzQ0IzIwMDM4MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fluidigm-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525466"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525466\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}